title: Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia.
abstract: In order to study the influence of bone marrow CD34(+) cell dose on the outcome of allogeneic bone marrow transplantation (BMT), we analysed the results of BMT from HLA-identical siblings donors in 50 patients with chronic myeloid leukaemia (CML). The median numbers of nucleated cells (NC) and CD34(+) cells infused were 2.18 x 10(8)/kg (0.05-4.14 x 10(8)/kg) and 3.12 x 10(6)/kg (0.35-8.52 x 10(6)/kg), respectively. All patients engrafted. In univariate analysis, there was no correlation between the number of CD34(+) cells infused and the time to neutrophil recovery (P = 0.17). The Kaplan-Meier estimate of grade II-IV acute graft-versus-host disease (GVHD) at day 100 was 53 +/- 14% and 2-year survival was 46 +/- 15%. A number of CD34(+) cells infused greater than the median was the main factor increasing survival (P = 0.0006) and decreasing 100 day transplant-related mortality (P = 0.009). Patient-, disease- and transplant-related characteristics were not statistically different among patients receiving more or less than the median number of CD34(+) cells. The rate of infectious deaths was significantly higher in patients receiving less than 3.12 x 10(6) CD34/kg (48% vs 16%, P = 0.01). In a multivariable analysis, two factors associated with increased risk of death were advanced disease status at transplant (HR: 2.5 (95% CI: 1.09-5.75), P = 0.03) and a lower number of marrow CD34(+) cells infused/kg (HR: 4.55 (95% CI: 1.87-10.90), P = 0.0008).
authors.affiliation: Laboratory of Cellular Therapy, Saint Louis Hospital, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Morariu-Zamfir
authors.forename: V
authors.initials: V
authors.lastname: Rocha
authors.forename: A
authors.initials: A
authors.lastname: Devergie
authors.forename: G
authors.initials: G
authors.lastname: Socié
authors.forename: P
authors.initials: P
authors.lastname: Ribaud
authors.forename: H
authors.initials: H
authors.lastname: Esperou
authors.forename: N
authors.initials: N
authors.lastname: Parquet
authors.forename: P
authors.initials: P
authors.lastname: Guardiola
authors.forename: L
authors.initials: L
authors.lastname: Dal Cortivo
authors.forename: H
authors.initials: H
authors.lastname: Bittencourt
authors.forename: F
authors.initials: F
authors.lastname: Garnier
authors.forename: R
authors.initials: R
authors.lastname: Traineau
authors.forename: J P
authors.initials: JP
authors.lastname: Marolleau
authors.forename: S
authors.initials: S
authors.lastname: Chevret
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis* / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000166:cytology / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000276:immunology; D002423:Cause of Death; D002452:Cell Count; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006085:Graft Survival; D006086:Graft vs Host Disease; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009679:Nuclear Family; D015996:Survival Rate; D014185:Transplantation, Isogeneic / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34